Sirolimus

Drug Profile

Sirolimus

Alternative Names: AY 22989; CYPHER; CYPHER SELECT PLus; NEVO; NPC-12; NPC-12G; NSC 226080; NSC 606698; Rapalimus; Rapamune; Rapamycin

Latest Information Update: 14 Jun 2017

Price : $50

At a glance

  • Originator Wyeth
  • Developer Cordis Corporation; Food and Drug Administration; Le Bonheur Children's Hospital; National Center for Advancing Translational Sciences; Nobelpharma; Pfizer; Wyeth
  • Class Anti-infectives; Antifungals; Antineoplastics; Lactones; Macrolides; Polyenes; Pyridines
  • Mechanism of Action B cell inhibitors; Immunosuppressants; MTOR protein inhibitors; T lymphocyte inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Coronary artery restenosis; Lymphangioleiomyomatosis; Renal transplant rejection
  • Phase III Fibroma
  • Phase II Systemic lupus erythematosus
  • Discontinued Autosomal dominant polycystic kidney disease; Mycoses

Most Recent Events

  • 09 May 2017 Pfizer terminates a phase III trial in Renal transplant rejection in USA as the collaborator stopped the study (PO) (NCT01166724)
  • 01 Oct 2016 Nobelpharma completes a phase III trial in Fibroma (facial angiofibroma in tuberous sclerosis complex; In children, In adolescents, In adults, In the elderly) in Japan (NCT02635789)
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top